Fraction of IL-10+ and IL-17+ CD8 T cells is increased in MS patients in remission and during a relapse, but is not influenced by immune modulators

Journal of Neuroimmunology

Volumn 258, Issue 1-2, 2013, Pages 77-84

  Peelen, E ^a,b   Thewissen, M ^a   Knippenberg, S ^a,b   Smolders, J ^c   Muris, A H ^a,b   Menheere, P ^a   Cohen Tervaert, J W ^a   Hupperts, R ^a,b   Damoiseaux, J ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Zuyderland Medical Centre   (Netherlands)

^c ST ANTONIUS HOSPITAL   (Netherlands)

Author keywords

CD8; IL 10; IL 17; Immune modulation; Multiple sclerosis

Indexed keywords

25 HYDROXYVITAMIN D; BETA INTERFERON; COLECALCIFEROL; GAMMA INTERFERON; GLATIRAMER; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 4;

ADD ON THERAPY; ADULT; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DOSE RESPONSE; DRUG MEGADOSE; FEMALE; HUMAN; HUMAN CELL; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

ADULT; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; INTERLEUKIN-10; INTERLEUKIN-17; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PEPTIDES; RADIOIMMUNOASSAY; RECURRENCE; REMISSION INDUCTION; T-LYMPHOCYTE SUBSETS; VITAMIN D;

EID: 84876705798     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2013.02.014     Document Type: Article

References (41)

1. Ascherio A., Munger K.L. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann. Neurol. 2007, 61:288-299.
2. Babbe H., Roers A., Waisman A., Lassmann H., Goebels N., Hohlfeld R., Friese M., Schroder R., Deckert M., Schmidt S., Ravid R., Rajewsky K. Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J. Exp. Med. 2000, 192:393-404.
3. Becher B., Giacomini P.S., Pelletier D., McCrea E., Prat A., Antel J.P. Interferon-gamma secretion by peripheral blood T-cell subsets in multiple sclerosis: correlation with disease phase and interferon-beta therapy. Ann. Neurol. 1999, 45:247-250.
4. Boniface K., Blumenschein W.M., Brovont-Porth K., McGeachy M.J., Basham B., Desai B., Pierce R., McClanahan T.K., Sadekova S., de Waal Malefyt R. Human Th17 cells comprise heterogeneous subsets including IFN-gamma-producing cells with distinct properties from the Th1 lineage. J. Immunol. 2010, 185:679-687.
5. Comi G., Filippi M., Wolinsky J.S. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann. Neurol. 2001, 49:290-297.
6. Franciotta D., Zardini E., Bergamaschi R., Andreoni L., Cosi V. Interferon gamma and interleukin 4 producing T cells in peripheral blood of multiple sclerosis patients undergoing immunomodulatory treatment. J. Neurol. Neurosurg. Psychiatry 2003, 74:123-126.
7. Furlan R., Bergami A., Lang R., Brambilla E., Franciotta D., Martinelli V., Comi G., Panina P., Martino G. Interferon-beta treatment in multiple sclerosis patients decreases the number of circulating T cells producing interferon-gamma and interleukin-4. J. Neuroimmunol. 2000, 111:86-92.
8. Goodin D.S. Treatment of multiple sclerosis with human beta interferon. Int. MS J. 2005, 12:96-108.
9. Hoftberger R., Aboul-Enein F., Brueck W., Lucchinetti C., Rodriguez M., Schmidbauer M., Jellinger K., Lassmann H. Expression of major histocompatibility complex class I molecules on the different cell types in multiple sclerosis lesions. Brain Pathol. 2004, 14:43-50.
10. Huber M., Heink S., Pagenstecher A., Reinhard K., Ritter J., Visekruna A., Guralnik A., Bollig N., Jeltsch K., Heinemann C., Wittmann E., Buch T., Prazeres da Costa O., Brüstle A., Brenner D., Mak T.W., Mittrücker H.W., Tackenberg B., Kamradt T., Lohoff M. IL-17A secretion by CD8+ T cells supports Th17-mediated autoimmune encephalomyelitis. J. Clin. Invest. 2013, 123:247-260.
11. Huseby E.S., Liggitt D., Brabb T., Schnabel B., Ohlen C., Goverman J. A pathogenic role for myelin-specific CD8(+) T cells in a model for multiple sclerosis. J. Exp. Med. 2001, 194:669-676.
12. Inoges S., Merino J., Bandres E., De Castro P., Subira M.L., Sanchez-Ibarrola A. Cytokine flow cytometry differentiates the clinical status of multiple sclerosis (MS) patients. Clin. Exp. Immunol. 1999, 115:521-525.
13. Jacobsen M., Cepok S., Quak E., Happel M., Gaber R., Ziegler A., Schock S., Oertel W.H., Sommer N., Hemmer B. Oligoclonal expansion of memory CD8+ T cells in cerebrospinal fluid from multiple sclerosis patients. Brain 2002, 125:538-550.
14. Jurewicz A., Biddison W.E., Antel J.P. MHC class I-restricted lysis of human oligodendrocytes by myelin basic protein peptide-specific CD8 T lymphocytes. J. Immunol. 1998, 160:3056-3059.
15. Killestein J., Den Drijver B.F., Van der Graaff W.L., Uitdehaag B.M., Polman C.H., Van Lier R.A. Intracellular cytokine profile in T-cell subsets of multiple sclerosis patients: different features in primary progressive disease. Mult. Scler. 2001, 7:145-150.
16. Lalive P.H., Neuhaus O., Benkhoucha M., Burger D., Hohlfeld R., Zamvil S.S., Weber M.S. Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action. CNS Drugs 2011, 25:401-414.
17. Lysandropoulos A.P., Jaquiery E., Jilek S., Pantaleo G., Schluep M., Du Pasquier R.A. Vitamin D has a direct immunomodulatory effect on CD8+ T cells of patients with early multiple sclerosis and healthy control subjects. J. Neuroimmunol. 2011, 233:240-244.
18. Mallone R., Mannering S.I., Brooks-Worrell B.M., Durinovic-Bello I., Cilio C.M., Wong F.S., Schloot N.C. Isolation and preservation of peripheral blood mononuclear cells for analysis of islet antigen-reactive T cell responses: position statement of the T-Cell Workshop Committee of the Immunology of Diabetes Society. Clin. Exp. Immunol. 2011, 163:33-49.
19. Martin R. HLA class I: friend and foe of multiple sclerosis. Nat. Med. 2008, 14:1150-1151.
20. McGeachy M.J., Bak-Jensen K.S., Chen Y., Tato C.M., Blumenschein W., McClanahan T., Cua D.J. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat. Immunol. 2007, 8:1390-1397.
21. Meehan T.F., DeLuca H.F. CD8(+) T cells are not necessary for 1 alpha,25-dihydroxyvitamin D(3) to suppress experimental autoimmune encephalomyelitis in mice. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:5557-5560.
22. Mei F.J., Osoegawa M., Ochi H., Minohara M., Nan S., Murai H., Ishizu T., Taniwaki T., Kira J. Long-term favorable response to interferon beta-1b is linked to cytokine deviation toward the Th2 and Tc2 sides in Japanese patients with multiple sclerosis. J. Neurol. Sci. 2006, 246:71-77.
23. Muris A.H., Damoiseaux J., Smolders J., Cohen Tervaert J.W., Hupperts R., Thewissen M. Intracellular IL-10 detection in T cells by flowcytometry: the use of protein transport inhibitors revisited. J. Immunol. Methods 2012, 381:59-65.
24. Neumann H., Medana I.M., Bauer J., Lassmann H. Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases. Trends Neurosci. 2002, 25:313-319.
25. Ochi H., Wu X.M., Osoegawa M., Horiuchi I., Minohara M., Murai H., Ohyagi Y., Furuya H., Kira J. Tc1/Tc2 and Th1/Th2 balance in Asian and Western types of multiple sclerosis, HTLV-I-associated myelopathy/tropical spastic paraparesis and hyperIgEaemic myelitis. J. Neuroimmunol. 2001, 119:297-305.
26. Peelen E., Knippenberg S., Muris A.H., Thewissen M., Smolders J., Tervaert J.W., Hupperts R., Damoiseaux J. Effects of vitamin D on the peripheral adaptive immune system: a review. Autoimmun. Rev. 2011, 10:733-743.
27. Polman C.H., Reingold S.C., Banwell B., Clanet M., Cohen J.A., Filippi M., Fujihara K., Havrdova E., Hutchinson M., Kappos L., Lublin F.D., Montalban X., O'Connor P., Sandberg-Wollheim M., Thompson A.J., Waubant E., Weinshenker B., Wolinsky J.S. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann. Neurol. 2011, 69:292-302.
28. Pouly S., Becher B., Blain M., Antel J.P. Interferon-gamma modulates human oligodendrocyte susceptibility to Fas-mediated apoptosis. J. Neuropathol. Exp. Neurol. 2000, 59:280-286.
29. PRISMS Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998, 352:1498-1504.
30. Sepulcre J., Sanchez-Ibarrola A., Moreno C., de Castro P. Association between peripheral IFN-gamma producing CD8+ T-cells and disability score in relapsing-remitting multiple sclerosis. Cytokine 2005, 32:111-116.
31. Serafini B., Rosicarelli B., Magliozzi R., Stigliano E., Capello E., Mancardi G.L., Aloisi F. Dendritic cells in multiple sclerosis lesions: maturation stage, myelin uptake, and interaction with proliferating T cells. J. Neuropathol. Exp. Neurol. 2006, 65:124-141.
32. Smolders J., Menheere P., Thewissen M., Peelen E., Tervaert J.W., Hupperts R., Damoiseaux J. Regulatory T cell function correlates with serum 25-hydroxyvitamin D, but not with 1,25-dihydroxyvitamin D, parathyroid hormone and calcium levels in patients with relapsing remitting multiple sclerosis. J. Steroid Biochem. Mol. Biol. 2010, 121:243-246.
33. Smolders J., Peelen E., Thewissen M., Cohen Tervaert J.W., Menheere P., Hupperts R., Damoiseaux J. Safety and T cell modulating effects of high dose vitamin D3 supplementation in multiple sclerosis. PLoS One 2010, 5:e15235.
34. Smolders J., Hupperts R., Barkhof F., Grimaldi L.M., Holmoy T., Killestein J., Rieckmann P., Schluep M., Vieth R., Hostalek U., Ghazi-Visser L., Beelke M. Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial. J. Neurol. Sci. 2011, 311:44-49.
35. Stewart N., Simpson S., van der Mei I., Ponsonby A.L., Blizzard L., Dwyer T., Pittas F., Eyles D., Ko P., Taylor B.V. Interferon-beta and serum 25-hydroxyvitamin D interact to modulate relapse risk in MS. Neurology 2012, 79:254-260.
36. Sun D., Whitaker J.N., Huang Z., Liu D., Coleclough C., Wekerle H., Raine C.S. Myelin antigen-specific CD8+ T cells are encephalitogenic and produce severe disease in C57BL/6 mice. J. Immunol. 2001, 166:7579-7587.
37. Tzartos J.S., Friese M.A., Craner M.J., Palace J., Newcombe J., Esiri M.M., Fugger L. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am. J. Pathol. 2008, 172:146-155.
38. Veldman C.M., Cantorna M.T., DeLuca H.F. Expression of 1,25-dihydroxyvitamin D(3) receptor in the immune system. Arch. Biochem. Biophys. 2000, 374:334-338.
39. Wang H.H., Dai Y.Q., Qiu W., Lu Z.Q., Peng F.H., Wang Y.G., Bao J., Li Y., Hu X.Q. Interleukin-17-secreting T cells in neuromyelitis optica and multiple sclerosis during relapse. J. Clin. Neurosci. 2011, 18:1313-1317.
40. Zhang N., Bevan M.J. CD8(+) T cells: foot soldiers of the immune system. Immunity 2011, 35:161-168.
41. Zielinski C.E., Mele F., Aschenbrenner D., Jarrossay D., Ronchi F., Gattorno M., Monticelli S., Lanzavecchia A., Sallusto F. Pathogen-induced human TH17 cells produce IFN-gamma or IL-10 and are regulated by IL-1beta. Nature 2012, 484:514-518.